- Home
- TLSA vs SLS Comparison
TLSA vs SLS Comparison
Compare TLSA & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- SLS
- Stock Information
- Founded
- TLSA 2013
- SLS 2012
- Country
- TLSA United Kingdom
- SLS United States
- Employees
- TLSA N/A
- SLS N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- SLS Health Care
- Exchange
- TLSA Nasdaq
- SLS Nasdaq
- Market Cap
- TLSA 187.0M
- SLS 165.6M
- IPO Year
- TLSA 2000
- SLS N/A
- Fundamental
- Price
- TLSA $1.97
- SLS $1.63
- Analyst Decision
- TLSA
- SLS Strong Buy
- Analyst Count
- TLSA 0
- SLS 1
- Target Price
- TLSA N/A
- SLS $7.00
- AVG Volume (30 Days)
- TLSA 555.6K
- SLS 1.7M
- Earning Date
- TLSA 08-26-2025
- SLS 08-12-2025
- Dividend Yield
- TLSA N/A
- SLS N/A
- EPS Growth
- TLSA N/A
- SLS N/A
- EPS
- TLSA N/A
- SLS N/A
- Revenue
- TLSA N/A
- SLS N/A
- Revenue This Year
- TLSA N/A
- SLS N/A
- Revenue Next Year
- TLSA N/A
- SLS N/A
- P/E Ratio
- TLSA N/A
- SLS N/A
- Revenue Growth
- TLSA N/A
- SLS N/A
- 52 Week Low
- TLSA $0.63
- SLS $0.77
- 52 Week High
- TLSA $2.60
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- TLSA 49.01
- SLS 45.73
- Support Level
- TLSA $1.90
- SLS $1.50
- Resistance Level
- TLSA $2.53
- SLS $1.66
- Average True Range (ATR)
- TLSA 0.26
- SLS 0.10
- MACD
- TLSA -0.05
- SLS -0.00
- Stochastic Oscillator
- TLSA 12.50
- SLS 43.33
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.